NCT00442650

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Merck KGaA, Darmstadt, Germany · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: —

Summary

Multicentre, open label, phase III study. Subjects with moderate to severe psoriasis were given efalizumab subcutaneously once per week for the 12-week treatment period. Assessments involved physical examination, disease activity assessments, clinical laboratory tests (haematology, blood chemistry and standard urinalysis), evaluation of the Psoriasis Area and Severity Index (PASI), the Physician's Global Assessment (PGA), the Patient's Global Psoriasis Assessment (PGPA), the SF-36 Health Survey and psoriatic body surface area (BSA). The 12-week treatment period was followed by a 12-week follow-up (FU) period, during which other antipsoriatic medications were allowed. The same assessments were also performed in the 12-week FU period.

Conditions

• Moderate to Severe Psoriasis

Interventions

Type	Name	Description
DRUG	Efalizumab

Timeline

• Start date: 2004-01-01
• Primary completion: 2005-12-01
• Completion: 2005-12-01
• First posted: 2007-03-02
• Last updated: 2016-11-21

Locations

1 site across 1 country: Switzerland